Who we are
Japan Pharmaceutical Consulting is a service provided by PointPath.Biz, K. K. (PPBIZ; Yokohama, Japan) founded by Dr. Yutaka Waki. PPBIZ has provided consulting to Japanese pharmaceutical companies, small and large since 2008. Being successful with repeated business from Japanese companies, now expanding its group to serve foreign companies seeking opportunities in Japan, and companies wish to enter Japanese market place. Pharmaceutical industry experts will help and facilitate your pharmaceutical development activities.
We work as a team, and as a team we have expertise expanding from CMC, nonclinical, clinical, to regulatory. We will discuss with you to understand your needs, and agree on what you may need to achieve your goals. In many cases in pharmaceutical development, it will be wiser to form a team, a project team to accomplish the task we face. We will propose a team dedicated to work on your project, help you in building the plans for development or actual operations in Japan.
Our experiences in industry are, some with fifteen years but many with more than twenty five years or more in total. Most of us have worked with two or more pharmaceutical companies, or service providers within the pharmaceutical industry.
The changes from the old system to current ICH compliant GXP regulated systems, we have lived through it and know them from heart. We have worked with small start-up companies to large multi-national companies, and know the rules within the corporate culture.
We have basic scientists, medicinal chemists, pharmacologist, toxicologist, clinical pharmacologist, clinical development experts, and also patent experts in our group. We can evaluate the scientific potential of your compound as a pharmaceutical product, this is essential in helping clients in licensing deals. Our experiences as a team are not only in small molecules, but also in biologics such as antibodies.
With our wide network in pharmaceutical industry, we can connect you to the right people or company you need in your business.